NHS
Pan Mersey
Area Prescribing Committee

# TOFACITINIB film-coated tablets (XELJANZ® ▼) for ankylosing spondylitis

## The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TOFACITINIB film-coated tablets (XELJANZ® ▼) for ankylosing spondylitis.

## GREY

Tofacitinib has been granted a license extension and is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.[1]

This recommendation will be reviewed when the NICE TA is published.

In the meantime, treatment of ankylosing spondylitis should continue to follow national guidance, local pathways and local formulary choices:

- NICE Guideline NG65: Spondyloarthritis in over 16s: diagnosis and management , last updated 02 June 2017
- Pan Mersey APC Guideline: Use of biological agents in the management of ankylosing spondylitis and non-radiographic axial spondyloarthritis, last updated 31 January 2018
- Pan Mersey APC Pathway: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (Axial SpA) pathway, last updated 23 September 2020

**References**

1. Pfizer Limited. Summary of Product Characteristics; XELJANZ 5 mg film-coated tablets, 01 February 2022. Accessed online 18 March 2022.

**Note**: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.